Next, we knocked down NAT10 in DDX21-overexpressing CRC cells and performed acRIP-qPCR experiments to assess the levels of ac4C modification on ATAD2, SOX4, and SNX5. This evidence concerns the gene NAT10 and colorectal carcinoma.